These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33451174)

  • 1. An EUA for casirivimab and imdevimab for COVID-19.
    Med Lett Drugs Ther; 2020 Dec; 62(1614):201-202. PubMed ID: 33451174
    [No Abstract]   [Full Text] [Related]  

  • 2. An EUA for bamlanivimab and etesevimab for COVID-19.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
    [No Abstract]   [Full Text] [Related]  

  • 3. An EUA for sotrovimab for treatment of COVID-19.
    Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630
    [No Abstract]   [Full Text] [Related]  

  • 4. An EUA for bamlanivimab - a monoclonal antibody for COVID-19.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):185-186. PubMed ID: 33443490
    [No Abstract]   [Full Text] [Related]  

  • 5. Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19.
    Med Lett Drugs Ther; 2021 Aug; 63(1631):130-131. PubMed ID: 34544100
    [No Abstract]   [Full Text] [Related]  

  • 6. Casirivimab/Imdevimab: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).
    Mayer C; VanHise K; Caskey R; Naqvi M; Burwick RM
    Obstet Gynecol; 2021 Dec; 138(6):937-939. PubMed ID: 34583385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.
    Wolf J; Abzug MJ; Wattier RL; Sue PK; Vora SB; Zachariah P; Dulek DE; Waghmare A; Olivero R; Downes KJ; James SH; Pinninti SG; Yarbrough A; Aldrich ML; MacBrayne CE; Soma VL; Grapentine SP; Oliveira CR; Hayes M; Kimberlin DW; Jones SB; Bio LL; Morton TH; Hankins JS; Maron GM; Timberlake K; Young JL; Orscheln RC; Schwenk HT; Goldman DL; Groves HE; Huskins WC; Rajapakse NS; Lamb GS; Tribble AC; Lloyd EC; Hersh AL; Thorell EA; Ratner AJ; Chiotos K; Nakamura MM
    J Pediatric Infect Dis Soc; 2021 May; 10(5):629-634. PubMed ID: 33388760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An EUA for baricitinib (Olumiant) for COVID-19.
    Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175
    [No Abstract]   [Full Text] [Related]  

  • 11. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019.
    Riccardo BA; Gabriele S; Nunzia E; Isabella DF; Biagio P; Maria F; Emanuela Z; Agnese G; Nicola SM; Giulio V; Riccardo S; Giuseppe B; Ivan G
    Am J Perinatol; 2024 May; 41(S 01):e612-e616. PubMed ID: 35973799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience.
    Dhand A; Lobo SA; Wolfe K; Feola N; Lee L; Nog R; Chen D; Glicklich D; Diflo T; Nabors C
    Transplantation; 2021 Jul; 105(7):e68-e69. PubMed ID: 33724242
    [No Abstract]   [Full Text] [Related]  

  • 13. Eua for Regen-Cov Now Includes COVID-19 Postexposure Prophylaxis.
    Aschenbrenner DS
    Am J Nurs; 2021 Nov; 121(11):22. PubMed ID: 34673689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An EUA for tocilizumab (Actemra) for COVID-19.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):113-114. PubMed ID: 34544106
    [No Abstract]   [Full Text] [Related]  

  • 15. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
    Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
    JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19.
    Aschenbrenner DS
    Am J Nurs; 2021 Feb; 121(2):26. PubMed ID: 33497123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.
    JAMA; 2021 Mar; 325(9):880-881. PubMed ID: 33306087
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
    J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
    McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
    JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofatumumab (Kesimpta) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Dec; 62(1614):203-205. PubMed ID: 33451176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.